On April 2, 2024, Martine Rothblatt, the Chairperson & Chief Executive Officer of United Therapeutics Corp (UTHR, Financial), sold 30,000 shares of the company. The transaction was reported in a SEC Filing.
United Therapeutics Corp is a biotechnology company focused on developing and commercializing innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company's portfolio includes treatments for pulmonary arterial hypertension and other cardiovascular disorders, as well as products in the fields of pediatric medicine and infectious disease.
Over the past year, the insider has sold a total of 458,425 shares and has not made any purchases. The recent sale by the insider is part of a trend observed over the past year, where there have been no insider buys and 53 insider sells for United Therapeutics Corp.
On the day of the sale, shares of United Therapeutics Corp were trading at $228.69, resulting in a market cap of $10.886 billion. The company's price-earnings ratio stands at 11.65, which is lower than the industry median of 29.035 and also below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 0.84, with a GF Value of $273.38, indicating that United Therapeutics Corp is modestly undervalued according to GuruFocus's valuation. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
The insider's recent transaction could be of interest to investors as it may signal their perspective on the company's current valuation and future prospects.
Investors often monitor insider transactions as they can provide insights into the company's performance and insider perspectives on the stock's value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
